Hadassah

FDA Grants Approval for US Clinical Trials of Hadassah-Developed Technology to Treat Fatty Liver Disease

Wednesday, Dec 17 2014

A new drug technology, developed at the Hadassah Medical Organization to treat fatty liver disease--a condition with no approved effective drug treatment--was given the go-ahead by the United States Food and Drug Administration (FDA) for a Phase 2 multi-center clinical trial in the US.

In its severe form (called nonalcoholic steatohepatitis-NASH), fatty liver disease can lead to cirrhosis and liver cancer. Current estimates reveal that at least five percent of the Western world’s population suffers from the disease. The majority of these patients also have diabetes, high blood lipids, and obesity.

The new technology was developed by Prof. Yaron Ilan, Director, Department of Internal Medicine and former president of the Israel Liver Association, and his team in Hadassah’s Liver Unit. Based on feeding natural antibodies against intestinal bacteria associated with fatty liver disease, the treatment reduces inflammation by directly affecting the activity level of regulatory T cells in the liver and fat tissues. “The new drug is based on a novel discovery that bacteria in our gut are relevant for the induction of inflammation in our body, which is associated with liver disease, diabetes, and obesity” said Prof. Ilan. “The new therapy is safe and has no side effect, and we hope the results of the phase II trial will enable us to move forward with its development as a treatment for diabetes and fatty liver disease”.

Hadasit, Hadassah’s technology transfer arm, and Immuron, an Australian biopharmaceutical company, worked together to develop the product. The collaborative effort combines Hadassah’s oral immune modulation approach with antibodies produced by Immuron.

The multi-center clinical trial will involve 120 patients in several leading medical centers in the US and Australia. The cohort will receive the treatment for six months, while monitored for the state of their liver disease, diabetes, and lipid profile.

Clinical trials were already conducted at Hadassah, which confirmed the safety and efficacy of the treatment.

Read about the 2009 discovery of treatment for fatty liver disease

Comments

No comments yet.
First Name
Email
Comment
Enter this word:

Related Stories

alt_text

Friday, Dec 8 2017

Israeli Start-Up Partners with Health Industry Leaders to Enhance Assessment of Head Trauma

MedyMatch Technology, an Israeli startup that has developed an artificial intelligence-based software to help clinicians more accurately assess head trauma or stroke...

READ MORE ›
alt_text

Friday, Dec 8 2017

Listening Beyond Eight Seconds

How long does the average doctor give a patient to tell her or him what’s wrong?

READ MORE ›
alt_text

Wednesday, Dec 6 2017

Hadassah and Australia Research Institute Sign MOU to Collaborate

A Memorandum of Understanding (MOU) to cooperate on scientific research in the fields of cardiovascular and diabetes medicine was signed on August 31 between the Hadassah Medical Organization and the Baker Heart and Diabetes Research Institute in Melbourne, Australia.

READ MORE ›
alt_text

Wednesday, Dec 6 2017

Hadassah’s Globally Renowned Ophthalmologist Receives International Recognition

Prof. Yaacov Pe’er, Immediate Past Director of the Hadassah Medical Organization’s Ophthalmology Department, has been honored with the American Academy of Ophthalmology (AAO)’s annual prize for his contributions to the field of ophthalmology and the prevention of blindness around the world.

READ MORE ›

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Missions Department

missions@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More